Françoise B.
- Country
- France
- Department
- Service ENMG et pathologie neuromusculaire
Research Overview
- Evaluation of Nipocalimab Efficacy and Safety in Adults with Seropositive Generalized Myasthenia Gravis: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study
- Long-term Safety and Efficacy Assessment of Intravenous Cipaglucosidase Alfa Co-administered with Oral Miglustat in Adults with Late-onset Pompe Disease
- Efficacy and Safety Evaluation of Metformin Hydrochloride in Myotonic Dystrophy Type 1: A Phase III Randomized, Double-Blind, Multicenter Study
Data & Insights
Has run more than one trial at 40 of 142 partner sites.
Specializations
Neuromuscular Disorders
This investigator specializes in treating patients with myotonic dystrophy type 1 (DM1), conducting research into therapeutic interventions using metformin for muscle function improvement in affected individuals.
- Muscle Function Assessment
- DM1 Treatment Development
Metabolic Storage Disorders
The investigator focuses on treating Pompe disease, particularly exploring novel therapeutic approaches including avalglucosidase alfa and the ATB200/AT2221 combination therapy for patients with late onset Pompe disease (LOPD).
- Glycogen Storage Disease Management
- Long-term Treatment Efficacy
Autoimmune Neurology
The investigator conducts research in generalized myasthenia gravis (gMG), evaluating innovative treatments including nipocalimab for improving daily living activities in seropositive patients.
- Novel Antibody Therapies
- Quality of Life Assessment
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.